Teva Pharmaceutical Industries Ltd.

Basel St 5
Petah Tikva, Center District

Teva Pharmaceutical Industries Ltd. News

TEVA PHARMACEUTICAL INDUSTRIES LTD.: Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the publication of data from the Phase III HALO study evaluating the efficacy, safety, and tolerability of both quarterly (every three months) and monthly subcutaneous dosing regimens of fremanezumab for the prevention of episodic migraine (EM). Read More »